Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, in Phase 3 development for Familial Adenomato... Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, in Phase 3 development for Familial Adenomatous Polyposis; tolimidone, in Phase 2 development for the treatment of type 1 diabetes; and MTX110, in Phase 1 development in aggressive rare/orphan brain cancer indications. Show more
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
Symbole | Prix | Vol. |
---|---|---|
TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 729,72M |
NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,54M |
RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 338,75M |
BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,29M |
CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 234,8M |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales